What is SilcsBio?
SilcsBio is at the forefront of computer-aided drug design (CADD), offering innovative software solutions such as SILCS, SILCS-Biologics, and CGenFF. These tools are designed to accelerate drug discovery timelines and reduce development costs for pharmaceutical and biotechnology firms. By generating detailed 3D free energy maps, SilcsBio's proprietary technology aids in the identification of critical drug targets, thereby optimizing drug development pipelines. The company also provides expert consultation and training services to enhance the efficacy of these processes.
How much funding has SilcsBio raised?
SilcsBio has raised a total of $1.3M across 1 funding round:
Other Financing Round
$1.3M
Other Financing Round (2016): $1.3M with participation from National Institute of Health
Key Investors in SilcsBio
National Institute of Health
The National Institute of Health is a prominent governmental agency focused on biomedical research, likely investing in SilcsBio to advance drug discovery technologies and methodologies.
What's next for SilcsBio?
The recent major strategic investment positions SilcsBio for accelerated expansion and further technological advancement. This capital infusion is expected to bolster the company's research and development efforts, potentially leading to new software features or expanded service offerings in CADD. SilcsBio's focus on optimizing drug discovery pipelines aligns with the increasing demand for efficient and cost-effective solutions in the life sciences industry, suggesting a strong future outlook for the company as it continues to scale its operations and market presence.
See full SilcsBio company page
